Multi-faceted method to repress reproduction of latent viruses in humans and animals
AssigneeHIV Diagnostics, Inc.
InventorKnox Van Dyke
Life of this patent
Estimating the term…
Abstract
Disclosed are methods for repressing reproduction of latent viruses, such as HIV, in animals by the generally concurrent administration of (1) antioxidants including a glutathione agent; and (2) an NFKB induction inhibitor. Also disclosed are pharmaceutical compositions and kits for use in repressing reproduction of latent viruses such as HIV.
Claims32
A method for suppressing the reproduction of a retrovirus in an animal comprising, administering to such animal:
- i) at least one agent in an amount effective to cause blood glutathione levels to increase, selected from the group consisting of glutathione, N-acetyl cysteine, 2-oxo-4 thiazolidine carboxylic acid. ebselen, oltipraz, L-cysteine, N-acetyl cysteine ethyl ester, N-acetyl cysteine methyl ester, cystamine, cysteamine. penicillamine, 2,3-dimercapto-1-propanol, L-2-oxothiazolidone-4-carboxylate, diethyl maleate, glutathione ethyl ester, glutathione methyl ester, glutathione isopropyl ester, oxazolidone. and combinations thereof,
- ii) at least one additional antioxidant at doses higher than the recommended daily minimum requirements;
- and
- iii) at least one NFKB induction inhibitor in an amount effective to inhibit nuclear factor kappa B;
- said at least one NFKB induction inhibitor being selected from the group consisting of anti-inflammatory steroids and nonglucocorticoid lazaroids.
A method for suppressing the reproduction of a lentivirus in an animal comprising, administering to such animal:
- i) at least one agent in an amount effective to cause blood glutathione levels to increase, selected from the group consisting of glutathione, N-acetyl cysteine, 2-oxo-4thiazolidine carboxylic acid, ebselen, oltipraz, L-cysteine, N-acetyl cysteine ethyl ester, N-acetyl cysteine methyl ester, cystamine, cysteamine, penicillamine, 2,3-dimercapto-1-propanol, L-2-oxothiazolidone-4-carboxylate, diethyl maleate, glutathione ethyl ester, glutathione methyl ester, glutathione isopropyl ester, oxazolidone, and combinations thereof;
- ii) at least one additional antioxidant at doses higher than the recommended daily minimum requirements;
- and
- iii) at least one NFKB induction inhibitor in an amount effective to inhibit nuclear factor kappa B;
- said at least one NFKB induction inhibitor being selected from the group consisting of anti-inflammatory steroids and nonglucocorticoid lazaroids.
The method of claim 76 wherein said fat-soluble antioxidant is selected from the group consisting of Vitamin A, Vitamin E and Vitamin K.
The method of claim 86 wherein said lazaroid is selected from the group consisting of 21-4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl!-16-methyl-(16.a lpha.)-pregna-1,4,9(11)-triene-3,20-dione monomethanesulfonate;
- 21-4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl!-pregna-1,4,9(11 )-triene-3,20-dione, (Z)2- 2-butenedioate(1:1)pregna-1,4,9(11)-triene-3,20-dione, 21-4-5,6-bis(diethylamino)-2--pyridinyl!-1-piperazinyl!-16-methyl-, hydrochloride, (16.alpha.);21 -4-3-(ethylamino)-2-pyridinyl!-1-piperazinyl-16-methyl-pregna-1,4,9(11)- trien-3,20-dione, (16.alpha.)-, (Z)-2-butenedioate(1:1);
- 2-4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl!-methyl!-3,4-dih ydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol, dihydrochloride;
- 2H-1-benzopyran-6-ol,2-4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperaz inyl!methyl!-3,4-dihydro-2,5,7,8-tetramethyl-1,2-hydroxy-1,2,4-propanetrica rboxylate(1:2);
- 2H-1-benzopyran-6-ol, 2-4-3)ethylamino)-2-pyridinyl!-1-piperazinyl!methyl!-3,4-dihydro-2,5,7, 8-tetramethyl-, hydrochloride;
- ethanol, 2-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl) methylamino!-;
- and (-)-24-(2,6-di-1-pyrollidinyl-4-pyrimidinyl)-1-piperazinyl methyl!-3,4-dihydro-2,5,7,8-tetramethyl-2H-1 -benzopyran-6-ol, dihydrochloride.
Dependencies are inferred from the claim text.